Wells Fargo Maintains Overweight on Axsome Therapeutics, Raises Price Target to $255

Benzinga Newsdesk www.benzinga.com Positive 79.1%

Neg 0% Neu 0% Pos 79.1%

Wells Fargo analyst Benjamin Burnett maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and raises the price target from $225 to $255.